

Report Information

More information from: <https://www.marketresearchfuture.com/reports/human-genetics-market-714>

Human Genetics Market Research Report—Global Forecast till 2032

Report / Search Code: MRFR/HC/0243-CR

Publish Date: February, 2022

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 3250.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Global Human Genetics Market Overview

Human Genetics Market Size was valued at USD 25.9 Billion in 2022. The Human Genetics market industry is projected to grow from USD 28.69Billion in 2023 to USD 65.18 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.80% during the forecast period (2023 - 2032). Growing demand for personalized medicine, rising research activities in genomics, increasing investments in genomics and genetic testing companies, rising prevalence of genetic disorders, advances in genomic technologies, are the key market drivers enhancing the market growth.

Human Genetics Market

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Using genomic tools in therapeutic settings has also altered human genetics as a scientific discipline. More people now have access to more affordable genetic testing, allowing for earlier and more accurate diagnosis of hereditary diseases. Genetic information is now being used to guide treatment decisions, pinpoint causes of disease, and determine the most effective medications and dosing schedules for individual patients. The advent of personalized medicine, in which care is tailored to an individual's genetic makeup, is made possible by these technological advancements. Hence, fueling economic growth in the Human Genetics industry.

There are only a handful of places where human genetics has been put to use so far. On the other hand, prosperous expansion is anticipated in the years to come. With the help of computational biology, we'll have plenty of room to keep track of all the genetic data we collect from people all around the world. Furthermore, as human genetics finds more and more uses in molecular diagnostic testing, market players may expect to see a sizable increase in income.

The need for gene therapy is rising rapidly because of the alarming rise in the incidence of genetic illnesses around the world. To respond, scientists in R&D and forensics labs are digging deep into human DNA to discover new, more effective treatments for a wide range of illnesses. The project has the backing of governments around the world, which are spending extensively in the human genetics industry to raise public knowledge of genetic illnesses, available therapies, and their impact on daily life.

July 2023: An analysis of 13 research by the National Institutes of Health showed that taking a "genotype-first" approach to patient care was beneficial, especially for diagnosing uncommon illnesses. This method aids in the identification of previously unknown gene-disease associations, broadens our understanding of previously characterized illnesses, and sheds light on emerging pathologies.

Human Genetics Market Trends

- **Modernization of genomic technologies is driving the market growth**

The Human Genetics Market has seen a radical transformation as a result of advances in genomic technology, which have completely changed how genetic data is analysed, comprehended, and used. Our knowledge of the human genome and its implications for the diagnosis, treatment, and prevention of disease has been greatly improved by this technologies. The creation and widespread use of next-generation sequencing (NGS) technologies is one of the most important developments. In comparison to conventional sequencing techniques, NGS enables researchers to rapidly and inexpensively sequence substantial volumes of genetic material. The ability to examine complete genomes, find disease-causing mutations, and find novel genetic variants linked to diverse illnesses has been made possible thanks to a significant increase in the speed and efficiency of genetic analysis.

In the field of human genetics, the development of CRISPR-Cas9 gene editing technology has likewise revolutionised research. The precise and targeted gene editing capabilities of CRISPR-Cas9 provide previously unheard-of chances for therapeutic interventions and potential treatments for hereditary disorders. Now that genetic sequences can be changed, mutations can be fixed, and the functional implications of certain gene changes can be studied, new opportunities for personalised medicine and gene therapies are now available.

High-throughput genotyping techniques have also become more popular in human genetics research. These platforms allow for the simultaneous investigation of thousands or even millions of genetic markers, revealing important information about population genetics, disease risk factors, and complicated genetic features. Genome-wide association studies (GWAS) that uncover genetic variations linked to prevalent diseases have been considerably enhanced by high-throughput genotyping, opening the door to better risk prediction, early identification, and individualised treatment approaches. Additionally, the management and interpretation of the enormous volumes of genetic data produced by these technologies have been made possible by advances in data processing and bioinformatics tools. The huge genetic information may be searched for patterns, correlations, and possible treatment targets thanks to sophisticated computing algorithms and machine learning approaches. This has facilitated the creation of more efficient diagnostics and therapies by accelerating the discovery of biomarkers, pharmacological targets, and genetic pathways implicated in diseases. The science of human genetics has also changed as a result of the incorporation of these genomic technologies into clinical practise. Genetic testing is becoming more widely available and more reasonably priced, enabling earlier and more precise detection of genetic illnesses. Clinicians can now use genetic data to influence therapy choices, identify illness risk factors, and select the best drugs and dosage schedules for specific patients. These technical developments have enabled the shift to personalised medicine, where treatment plans are customised to a patient's genetic profile. Thus, driving the Human Genetics market revenue.

Human Genetics Market Segment Insights

Human Genetics Application Insights

The Human Genetics market segmentation, based on Application includes Wellness & E-Commerce, Preventive Medicine and Diagnostic & Treatment. The diagnostic & treatment segment dominated the market, accounting for 46.25% of market revenue. Due to its crucial role in clinical decision-making and therapeutic treatments, the Diagnostic & Treatment subsegment is projected to dominate the market.

Figure 1: Human Genetics Market, by Application, 2022 & 2032 (USD Billion)

Human Genetics Market, by Application, 2022 & 2032

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Human Genetics Test Insights

The Human Genetics market segmentation, based on Test, includes NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others. The NIPT category generated the most income of 33.42%. Considering it is non-invasive and has a high degree of accuracy, NIPT has become increasingly popular.

July 2023: Novartis Espana, a division of the world's largest pharmaceutical company, and DBGen Ocular Genomics, a spinoff of the University of Barcelona, have formed a partnership that will allow patients with retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) to identify their underlying genetic causes by July 2023. Using mass sequencing of gene panels produced by the UB spin-off, DBGen Ocular Genomics and Novartis will be able to reliably determine the genetic basis of these two diseases.

July 2023: Scientists at the Centre for Cellular and Molecular Biology (CCMB) in an Indian city have created Optical Genome Mapping (OGM), a state-of-the-art, extremely costly next-generation genetic testing tool, in July 2023. Using OGM, genetic defects in humans can be identified with high accuracy. The term "New Generation Cytogenetics" was used to describe

Human Genetics Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Human Genetics Market dominated this market in 2022 (45.80%). The increasing popularity of personalised medicine and the high prevalence of genetic illnesses both support North America's market dominance... Further, the U.S. Human Genetics market held the largest market share, and the Canada Armor Materials market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HUMAN GENETICS MARKET SHARE BY REGION 2022 (USD Billion)

HUMAN GENETICS MARKET SHARE BY REGION 2022

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Human Genetics market accounts for the second-largest market share. Leading genomics businesses are present, precision medicine is becoming more of a focus, and regulatory frameworks are supportive of market expansion. Further, the German Human Genetics market held the largest market share, and the UK Human Genetics market was the fastest growing market in the European region

The Asia-Pacific Human Genetics Market is expected to grow at the fastest CAGR from 2023 to 2032. The market is expected to increase as a result of the area's huge population base, growing

awareness of genetic illnesses, and government measures to support genomics research and precision medicine. Moreover, China's Human Genetics market held the largest market share, and the Indian Human Genetics market was the fastest growing market in the Asia-Pacific region.

Human Genetics Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Human Genetics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Human Genetics industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Human Genetics industry to benefit clients and increase the market sector. In recent years, the Human Genetics industry has offered some of the most significant advantages to medicine. Major players in the Human Genetics market, including Myriad Genetics (US), Synlab Group (Germany), Eurofins Megalab S.A (Spain), Biomarker Technology (US), Echevarne Laboratory (Spain), Elabscience Biotechnology Inc (US), NIMGenetics (Spain), Sistemas Genómicos (Spain), FullGenomics (Spain), GENinCode (UK), Atrys Health (Spain), and others, are attempting to increase market demand by investing in research and development operations.

Myriad Genetics, based in the United States, is a leading company in the Human Genetics Market. Founded in 1992, the business specialises in solutions for personalised medicine and genetic testing. Myriad Genetics provides a variety of genetic tests that aid in illness risk assessment, diagnosis, and therapy choice, with a major emphasis on oncology, hereditary diseases, and reproductive health. The BRAC Analysis test, the company's main product, is well-known for determining the risk of hereditary breast and ovarian cancer brought on by mutations in the BRCA1 and BRCA2 genes. Myriad Genetics has increased the number of genetic tests available in its test portfolio, such as Vectra DA for rheumatoid arthritis, GeneSight Psychotropic, and my Risk Hereditary Cancer. These tests offer insightful data about disease propensity, treatment effectiveness, and personalised medicine strategies.

Biomarker Technology, based in the United States, is a prominent company operating in the Human Genetics Market. Biomarker Technology, a company founded with the goal of enhancing biomarker research and development, focuses on the discovery and validation of genetic and protein-based biomarkers for a variety of illnesses and ailments. In order to facilitate the conversion of biomarker research into clinical applications, the company provides a variety of services and solutions. Their proficiency in genomes, proteomics, and bioinformatics enables them to create state-of-the-art tools and platforms for the discovery, verification, and use of biomarkers. To aid in the development of personalised medical methods, Biomarker Technology works with pharmaceutical companies, academic institutions, and research organizations. They make use of their skills to support the creation of companion diagnostics, biomarker analysis, and clinical trial design.

Key Companies in the Human Genetics market include

- Myriad Genetics (US)
- Synlab Group (Germany)
- Eurofins Megalab S.A (Spain)
- Biomarker Technology (US)
- Echevarne Laboratory (Spain)
- Elabscience Biotechnology Inc (US)
- NIMGenetics (Spain)
- Sistemas Genómicos (Spain)
- FullGenomics (Spain)

- GENinCode (UK)
- Atrys Health (Spain)

Human Genetics Industry Developments

2021-*Eversana will assist GENinCode in gaining entry to the US market for its portfolio of polygenic cardiovascular disease treatments, which are primarily focused on hereditary risk. GENinCode announced its agreement with Eversana as its launch and commercialization partner.*

2019-*In the field of oncology, Myriad Genetics and Illumina has formed a strategic alliance. A time-limited exclusive agreement for Illumina to provide a kit-based version of the myChoice CDx test for international markets is part of the strategic partnership between Myriad and Illumina.*

Human Genetics Market Segmentation

Human Genetics Application Outlook

- Wellness & E-Commerce
- Preventive Medicine
- Diagnostic & Treatment

Human Genetics Test Outlook

- NIPT
- Carrier Testing
- Pharmacogenomic Testing
- Karyotype Testing
- Thrombophilia Testing
- Septin 9 Biomarker Testing
- NGS
- Others

Human Genetics Regional Outlook

- North America
- U.S.

- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
 - China
 - Japan
 - India
 - Australia
 - South Korea
 - Australia
 - Rest of Asia-Pacific
- Rest of the World
 - Middle East
 - Africa
 - Latin America

TABLE OF CONTENTS	
1 EXECUTIVE SUMMARY	14
2 MARKET INTRODUCTION	15
2.1 DEFINITION	15
2.2 SCOPE OF THE STUDY	15
2.3 RESEARCH OBJECTIVE	15
2.4 MARKET STRUCTURE	15
2.5 ASSUMPTIONS & LIMITATIONS	16
3 RESEARCH METHODOLOGY	17
3.1 DATA MINING	17
3.2 SECONDARY RESEARCH	18
3.3 PRIMARY RESEARCH	19
3.4 BREAKDOWN OF PRIMARY RESPONDENTS	20
3.5 FORECASTING TECHNIQUES	21
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION	22
3.6.1 BOTTOM-UP APPROACH	23
3.6.2 TOP-DOWN APPROACH	23
3.7 DATA TRIANGULATION	24
3.8 VALIDATION	24
4 MARKET DYNAMICS	25
4.1 OVERVIEW	25
4.2 DRIVERS	26
4.2.1 GROWING ADOPTION OF GENETIC TESTING	26
4.2.2 INCREASING INCIDENCES OF GENETIC DISEASES AND CANCER	26
4.3 RESTRAINTS	27
4.3.1 HIGH COST OF GENETIC TESTING	27
4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED GENETIC COUNSELORS	27
4.4 OPPORTUNITY	28
4.4.1 GROWING USE OF GENETIC DATA ACROSS HEALTHCARE AND TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING	28
5 MARKET FACTOR ANALYSIS	29
5.1 VALUE CHAIN ANALYSIS	29
5.1.1 R&D	30
5.1.2 MANUFACTURING	30
5.1.3 DISTRIBUTION & SALES	30
5.1.4 POST-SALES MONITORING	30
5.2 PORTER'S FIVE FORCES MODEL	31
5.2.1 THREAT OF NEW ENTRANTS	31
5.2.2 BARGAINING POWER OF SUPPLIERS	32
5.2.3 THREAT OF SUBSTITUTES	32
5.2.4 BARGAINING POWER OF BUYERS	32
5.2.5 INTENSITY OF RIVALRY	32
5.3 IMPACT OF COVID-19 ON THE GLOBAL HUMAN GENETICS MARKET	32
5.3.1 IMPACT ON SUPPLY CHAIN	32
5.3.2 IMPACT ON PATIENTS SUFFERING FROM GENETIC DISEASES	33
5.3.3 IMPACT ON KEY PLAYERS	33
6 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION	34
6.1 OVERVIEW	34
6.2 WELLNESS & E-COMMERCE	35
6.3 PREVENTIVE MEDICINE	35
6.4 DIAGNOSTIC & TREATMENT	36
7 GLOBAL HUMAN GENETICS MARKET, BY TEST	42
7.1 OVERVIEW	42
7.2 NIPT	43
7.3 CARRIER TESTING	44
7.4 PHARMACOGENOMIC TESTING	45
7.5 KARYOTYPE TESTING	46
7.6 THROMBOPHILIA TESTING	47
7.7 SEPTIN 9 BIOMARKER TESTING	48
7.8 NGS	49
7.9 OTHERS	51
8 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY	52
8.1 OVERVIEW	52
8.1.1 US	53
8.1.2 CANADA	55
8.1.3 UK	57
8.1.4 GERMANY	59
8.1.5 SPAIN	61
8.1.6 JAPAN	63
8.1.7 OTHERS	65
9 COMPETITIVE LANDSCAPE	67
9.1 OVERVIEW	67
9.2 COMPETITIVE BENCHMARKING	68
9.3 MAJOR GROWTH STRATEGY IN THE HUMAN GENETICS MARKET	69
9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE HUMAN GENETICS MARKET	70
9.5 KEY DEVELOPMENT ANALYSIS	71
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES	71
9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL	71
9.6.2 MERGER & ACQUISITION	71
9.6.3 EXPANSION	72
9.7 FINANCIAL MATRIX	72
9.7.1 SALES (USD MILLION), 2020	72
10 COMPANY PROFILES	73
10.1 MYRIAD GENETICS, INC.	73
10.1.1 COMPANY OVERVIEW	73
10.1.2 FINANCIAL OVERVIEW	74

10.1.3	PRODUCT/SERVICE OFFERED	75
10.1.4	KEY DEVELOPMENTS	75
10.1.5	SWOT ANALYSIS	76
10.1.6	KEY STRATEGIES	76
10.2	SYNLAB GROUP	77
10.2.1	COMPANY OVERVIEW	77
10.2.2	FINANCIAL OVERVIEW	77
10.2.3	PRODUCT/SERVICE OFFERED	78
10.2.4	KEY DEVELOPMENTS	78
10.2.5	SWOT ANALYSIS	79
10.2.6	KEY STRATEGIES	79
10.3	EUROFINS MEGALAB S.A.	80
10.3.1	COMPANY OVERVIEWS	80
10.3.2	FINANCIAL OVERVIEW	80
10.3.3	PRODUCT/SERVICE OFFERED	81
10.3.4	KEY DEVELOPMENTS	81
10.3.5	SWOT ANALYSIS	81
10.3.6	KEY STRATEGIES	82
10.4	BIOMARKER TECHNOLOGIES.	83
10.4.1	COMPANY OVERVIEW	83
10.4.2	FINANCIAL OVERVIEW	83
10.4.3	PRODUCT/SERVICE OFFERED	83
10.4.4	KEY DEVELOPMENTS	83
10.4.5	SWOT ANALYSIS	84
10.4.6	KEY STRATEGIES	84
10.5	ECHEVARNE LABORATORY	85
10.5.1	COMPANY OVERVIEW	85
10.5.2	FINANCIAL OVERVIEW	85
10.5.3	PRODUCT/SERVICE OFFERED	85
10.5.4	KEY DEVELOPMENTS	85
10.5.5	SWOT ANALYSIS	86
10.5.6	KEY STRATEGIES	86
10.6	ELABSCIENCE BIOTECHNOLOGY INC.	87
10.6.1	COMPANY OVERVIEW	87
10.6.2	FINANCIAL OVERVIEW	87
10.6.3	PRODUCT/SERVICE OFFERED	87
10.6.4	KEY DEVELOPMENTS	87
10.6.5	SWOT ANALYSIS	88
10.6.6	KEY STRATEGIES	88
10.7	NIMGENETICS	89
10.7.1	COMPANY OVERVIEW	89
10.7.2	FINANCIAL OVERVIEW	89
10.7.3	PRODUCT/SERVICE OFFERED	89
10.7.4	KEY DEVELOPMENTS	90
10.7.5	SWOT ANALYSIS	90
10.7.6	KEY STRATEGIES	90
10.8	SISTEMAS GENÓMICOS	91
10.8.1	COMPANY OVERVIEW	91
10.8.2	FINANCIAL OVERVIEW	91
10.8.3	PRODUCTS/SERVICES OFFERED	91
10.8.4	KEY DEVELOPMENTS	91
10.8.5	SWOT ANALYSIS	92
10.8.6	KEY STRATEGIES	92
10.9	FULLGENOMICS	93
10.9.1	COMPANY OVERVIEW	93
10.9.2	FINANCIAL OVERVIEW	93
10.9.3	PRODUCTS/SERVICES OFFERED	93
10.9.4	KEY DEVELOPMENTS	93
10.9.5	SWOT ANALYSIS	94
10.9.6	KEY STRATEGIES	94
10.10	GENINCODE	95
10.10.1	COMPANY OVERVIEW	95
10.10.2	FINANCIAL OVERVIEW	95
10.10.3	PRODUCTS/SERVICES OFFERED	95
10.10.4	KEY DEVELOPMENTS	95
10.10.5	SWOT ANALYSIS	96
10.10.6	KEY STRATEGIES	96
10.11	ATRY'S HEALTH	97
10.11.1	COMPANY OVERVIEW	97
10.11.2	FINANCIAL OVERVIEW	97
10.11.3	PRODUCTS/SERVICES OFFERED	97
10.11.4	KEY DEVELOPMENTS	97
10.11.5	SWOT ANALYSIS	98
10.11.6	KEY STRATEGIES	98
10.12	GENYCA	99
10.12.1	COMPANY OVERVIEW	99
10.12.2	FINANCIAL OVERVIEW	99
10.12.3	PRODUCTS/SERVICES OFFERED	99
10.12.4	KEY DEVELOPMENTS	99
10.12.5	SWOT ANALYSIS	100
10.12.6	KEY STRATEGIES	100
10.13	IGENOMIX	101
10.13.1	COMPANY OVERVIEW	101
10.13.2	FINANCIAL OVERVIEW	101
10.13.3	PRODUCTS/SERVICES OFFERED	101
10.13.4	KEY DEVELOPMENTS	101
10.13.5	SWOT ANALYSIS	102
10.13.6	KEY STRATEGIES	102
10.14	GENOLÓGICA	103
10.14.1	COMPANY OVERVIEW	103
10.14.2	FINANCIAL OVERVIEW	103
10.14.3	PRODUCTS/SERVICES OFFERED	103
10.14.4	KEY DEVELOPMENTS	103

10.14.5 SWOT ANALYSIS	104
10.14.6 KEY STRATEGIES	104
10.15 BODE CELLMARK FORENSICS, INC.	105
10.15.1 COMPANY OVERVIEW	105
10.15.2 FINANCIAL OVERVIEW	105
10.15.3 PRODUCTS/SERVICES OFFERED	105
10.15.4 KEY DEVELOPMENTS	105
10.15.5 SWOT ANALYSIS	106
10.15.6 KEY STRATEGIES	106
11 APPENDIX	107
11.1 REFERENCES	107
11.2 RELATED REPORTS	107

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS	16
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS	19
TABLE 3 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)	34
TABLE 4 GLOBAL HUMAN GENETICS MARKET FOR WELLNESS & E-COMMERCE, BY COUNTRY, 2018–2027 (USD MILLION)	35
TABLE 5 GLOBAL HUMAN GENETICS MARKET FOR PREVENTIVE MEDICINE, BY COUNTRY, 2018–2027 (USD MILLION)	36
TABLE 6 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY COUNTRY, 2018–2027 (USD MILLION)	37
TABLE 7 GLOBAL HUMAN GENETICS MARKET FOR APPLICATION, BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION)	37
TABLE 8 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2027 (USD MILLION)	38
TABLE 9 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018–2027 (USD MILLION)	38
TABLE 10 GLOBAL HUMAN GENETICS MARKET FOR NEUROLOGY, BY COUNTRY, 2018–2027 (USD MILLION)	39
TABLE 11 GLOBAL HUMAN GENETICS MARKET FOR ASSISTED REPRODUCTION, BY COUNTRY, 2018–2027 (USD MILLION)	39
TABLE 12 GLOBAL HUMAN GENETICS MARKET FOR GYNECOLOGY, BY COUNTRY, 2018–2027 (USD MILLION)	40
TABLE 13 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION)	40
TABLE 14 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION)	40
TABLE 15 GLOBAL HUMAN GENETICS MARKET FOR NEUROPEDIATRIC, BY COUNTRY, 2018–2027 (USD MILLION)	41
TABLE 16 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION)	41
TABLE 17 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION)	43
TABLE 18 GLOBAL HUMAN GENETICS MARKET FOR NIPT, BY COUNTRY, 2018–2027 (USD MILLION)	44
TABLE 19 GLOBAL HUMAN GENETICS MARKET FOR CARRIER TESTING, BY COUNTRY, 2018–2027 (USD MILLION)	45
TABLE 20 GLOBAL HUMAN GENETICS MARKET FOR PHARMACOGENOMIC TESTING, BY COUNTRY, 2018–2027 (USD MILLION)	46
TABLE 21 GLOBAL HUMAN GENETICS MARKET FOR KARYOTYPE TESTING, BY COUNTRY, 2018–2027 (USD MILLION)	47
TABLE 22 GLOBAL HUMAN GENETICS MARKET FOR THROMBOPHILIA TESTING, BY COUNTRY, 2018–2027 (USD MILLION)	48
TABLE 23 GLOBAL HUMAN GENETICS MARKET FOR SEPTIN 9 BIOMARKER TESTING, BY COUNTRY, 2018–2027 (USD MILLION)	48
TABLE 24 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY COUNTRY, 2018–2027 (USD MILLION)	49
TABLE 25 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION)	49
TABLE 26 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2027 (USD MILLION)	49
TABLE 27 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018–2027 (USD MILLION)	50
TABLE 28 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION)	51
TABLE 29 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION)	51
TABLE 30 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY, 2018–2027 (USD MILLION)	52
TABLE 31 US: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)	53
TABLE 32 US: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION)	53
TABLE 33 US: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION)	54
TABLE 34 US: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION)	54
TABLE 35 US: HUMAN GENETICS MARKET FOR BY NGS, BY TYPE, 2018–2027 (USD MILLION)	54
TABLE 36 CANADA: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)	55
TABLE 37 CANADA: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION)	55
TABLE 38 CANADA: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION)	56
TABLE 39 CANADA: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION)	56
TABLE 40 CANADA: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION)	56
TABLE 41 UK: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)	57
TABLE 42 UK: HUMAN GENETICS MARKET FOR BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION)	57
TABLE 43 UK: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION)	58
TABLE 44 UK: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION)	58
TABLE 45 UK: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION)	58
TABLE 46 GERMANY: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)	59
TABLE 47 GERMANY: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION)	59
TABLE 48 GERMANY: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION)	60
TABLE 49 GERMANY: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION)	60
TABLE 50 GERMANY: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION)	60
TABLE 51 SPAIN: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)	61
TABLE 52 SPAIN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, FOR TYPE, 2018–2027 (USD MILLION)	61
TABLE 53 SPAIN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION)	62
TABLE 54 SPAIN: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION)	62
TABLE 55 SPAIN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION)	62
TABLE 56 JAPAN: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)	63

TABLE 57 JAPAN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 63
TABLE 58 JAPAN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 64
TABLE 59 JAPAN: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 64
TABLE 60 JAPAN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 64
TABLE 61 OTHERS: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 65
TABLE 62 OTHERS: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 65
TABLE 63 OTHERS: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 66
TABLE 64 OTHERS: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 66
TABLE 65 OTHERS: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 66
TABLE 66 MAJOR PLAYERS IN THE HUMAN GENETICS MARKET 67
TABLE 67 MOST ACTIVE PLAYER IN THE HUMAN GENETICS MARKET 70
TABLE 68 PRODUCT LAUNCH/PRODUCT APPROVAL 71
TABLE 69 MERGER & ACQUISITION 71
TABLE 70 EXPANSION 72
TABLE 71 MYRIAD GENETICS INC.: PRODUCT/SERVICE OFFERED 75
TABLE 72 MYRIAD GENETICS INC.: KEY DEVELOPMENTS 75
TABLE 73 SYNLAB GROUP: PRODUCT/SERVICE OFFERED 78
TABLE 74 SYNLAB GROUP: KEY DEVELOPMENTS 78
TABLE 75 EUROFINS MEGALAB S.A: PRODUCT/SERVICE OFFERED 81
TABLE 76 BIOMARKER TECHNOLOGIES: PRODUCT/SERVICE OFFERED 83
TABLE 77 ECHEVARNE LABORATORY: PRODUCT /SERVICE OFFERED 85
TABLE 78 ELABSCIENCE BIOTECHNOLOGY INC.: PRODUCT/SERVICE OFFERED 87
TABLE 79 NIMGENETICS: PRODUCT/SERVICE OFFERED 89
TABLE 80 SISTEMAS GENÓMICOS: PRODUCTS OFFERED 91
TABLE 81 FULLGENOMICS: PRODUCTS/SERVICES OFFERED 93
TABLE 82 GENINCODE: PRODUCTS/SERVICES OFFERED 95
TABLE 83 GENINCODE: KEY DEVELOPMENTS 95
TABLE 84 ATRYS HEALTH: PRODUCTS/SERVICES OFFERED 97
TABLE 85 GENYCA: PRODUCTS/SERVICES OFFERED 99
TABLE 86 IGENOMIX: PRODUCTS/SERVICES OFFERED 101
TABLE 87 IGENOMIX: KEY DEVELOPMENTS 101
TABLE 88 GENOLOGICA: PRODUCTS/SERVICES OFFERED 103
TABLE 89 BODE CELLMARK FORENSICS, INC.: PRODUCTS/SERVICES OFFERED 105

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 14
FIGURE 2 GLOBAL HUMAN GENETICS MARKET 15
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 22
FIGURE 4 MARKET DYNAMICS: GLOBAL HUMAN GENETICS MARKET 25
FIGURE 5 DRIVER IMPACT ANALYSIS 27
FIGURE 6 RESTRAINT IMPACT ANALYSIS 28
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL HUMAN GENETICS MARKET 29
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL HUMAN GENETICS MARKET 31
FIGURE 9 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 34
FIGURE 10 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2020 AND 2027 (USD MILLION) 42
FIGURE 11 GLOBAL HUMAN GENETICS MARKET SHARE (%), BY COUNTRY, 2020 52
FIGURE 12 BENCHMARKING OF MAJOR COMPETITORS 68
FIGURE 13 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE HUMAN GENETICS MARKET 69
FIGURE 14 HUMAN GENETICS MARKET: COMPETITIVE LANDSCAPE 71
FIGURE 15 SALES (USD MILLION), 2020 72
FIGURE 16 MYRIAD GENETICS INC.: FINANCIAL OVERVIEW SNAPSHOT 74
FIGURE 17 MYRIAD GENETICS INC.: SWOT ANALYSIS 76
FIGURE 18 SYNLAB GROUP: FINANCIAL OVERVIEW SNAPSHOT 77
FIGURE 19 SYNLAB GROUP: SWOT ANALYSIS 79
FIGURE 20 EUROFINS MEGALAB S.A.: FINANCIAL OVERVIEW SNAPSHOT 80
FIGURE 21 EUROFINS MEGALAB S.A: SWOT ANALYSIS 81
FIGURE 22 BIOMARKER TECHNOLOGIES: SWOT ANALYSIS 84
FIGURE 23 ECHEVARNE LABORATORY: SWOT ANALYSIS 86
FIGURE 24 ELABSCIENCE BIOTECHNOLOGY INC.: SWOT ANALYSIS 88
FIGURE 25 NIMGENETICS: SWOT ANALYSIS 90
FIGURE 26 SISTEMAS GENÓMICOS: SWOT ANALYSIS 92
FIGURE 27 FULLGENOMICS: SWOT ANALYSIS 94
FIGURE 28 GENINCODE: SWOT ANALYSIS 96
FIGURE 29 ATRYS HEALTH: SWOT ANALYSIS 98
FIGURE 30 GENYCA: SWOT ANALYSIS 100
FIGURE 31 IGENOMIX: SWOT ANALYSIS 102
FIGURE 32 GENOLOGICA: SWOT ANALYSIS 104
FIGURE 33 BODE CELLMARK FORENSICS, INC.: SWOT ANALYSIS 106